ABUSNasdaqPharmaceutical PreparationsFiscal year ends December 31

Arbutus Biopharma Corp

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026

$4.23+0.01 (+0.24%)

Close on Oct 19, 2026

Market cap: $835.30M
P/E (TTM): 5.4
Dividend yield: –

Arbutus Biopharma Corp income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31
Revenue	14	6.17	18	39	11	6.91	6.01	5.95	11	1.49	23	15	15	14	17	–
Research & Development	25	54	74	84	66	49	58	58	63	61	52	39	21	18	20	–
General & Administrative	16	22	22	18	17	15	18	16	16	39	26	8.68	5.55	8.14	6.39	–
Operating Expenses	52	82	96	104	85	65	150	96	122	493	127	48	28	27	28	–
Operating Income	-38	-76	-78	-65	-74	-58	-144	-90	-111	-492	-104	-33	-12	-13	-11	–
Interest Expense	0.10	0.14	0.46	1.73	2.86	4.01	2.11	0.23	0.26	0	0	–	–	–	–	–
Interest & Investment Income	4.07	6.59	5.69	2.19	0.13	0.74	2.11	3.05	1.54	1.39	0.67	0.85	0.54	0.14	0.13	–
Income from Equity Investments	–	–	–	–	0	-2.55	-23	-5.56	0	–	–	–	–	–	–	–
Other Non-Operating Income	4.66	6.40	5.25	0.44	-2.73	-5.94	-22	28	2.20	2.47	25	-5.40	-1.91	–	–	–
Merger & Restructuring Charges	13	3.72	0	–	0	0.06	0.16	4.80	0	–	–	–	–	–	–	–
Asset Impairment Charges	–	–	–	–	–	0	22	0	0	138	0	0	0	–	–	–
Gain (Loss) on Investments	–	–	–	–	–	–	–	25	0	–	–	–	–	–	–	–
Gain (Loss) on Sale of Assets	0.67	0	0.02	0	–	0	-0.02	0.03	0.00	-0.17	0	0.08	0	–	–	–
Pretax Income	–	–	–	–	–	-64	-166	-61	-109	-489	-79	-39	-14	–	–	–
Income Tax Expense	0	0	0	4.44	0	0	-13	-4.28	-24	-105	-16	0	0	–	–	–
Net Income	-34	-70	-73	-69	-76	-64	-154	-57	-84	-384	-63	-39	-14	30	-10	–
Net Income to Common	–	–	–	-69	-88	-76	-165	-67	-85	-384	-63	–	–	–	–	–
EPS (Basic)(per share)	-0.17	-0.38	-0.44	-0.46	-0.83	-1.00	-2.89	-1.21	-1.56	-7.24	-1.38	-1.80	-0.92	2.16	-0.89	–
EPS (Diluted)(per share)	-0.17	-0.38	-0.44	-0.46	-0.83	-1.00	-2.89	-1.21	-1.56	-7.24	-1.38	-1.80	-0.92	2.07	-0.89	–
Shares Outstanding (Basic, Weighted)(shares)	192	186	166	151	106	76	57	55	55	53	45	22	15	14	11	10
Shares Outstanding (Diluted, Weighted)(shares)	192	186	166	151	106	76	57	55	55	53	45	22	15	14	11	10

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: 82.0%
Net margin: 84.2%
Return on equity, FY2025: -38.5%

Financial strength

Current ratio: 81.42
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 569.9%

Valuation

P/E ratio: 5.4
Price to sales: 4.60
Price to book: 3.23
Dividend yield: –